ThirtyFiveBio Secures Funding for GI Treatment Advances
Groundbreaking Innovations in Gastrointestinal Treatment: The Rise of ThirtyFiveBio
In the competitive world of biotechnology, securing funding is crucial for startups aiming to revolutionize health care. ThirtyFiveBio, an emerging player based in Oxford, UK, has successfully closed a Bridge financing round that attracted notable participation from AbbVie Ventures, Canaan, and new investor Mayewell Capital. While the exact amount raised remains undisclosed, this funding leap signifies strong confidence in the company’s potential to disrupt treatments for gastrointestinal (GI) diseases.
At the heart of ThirtyFiveBio’s mission is the development of small molecule inhibitors targeting the G protein-coupled receptor 35 (GPR35), which has shown promise in treating conditions like colitis and GI-related cancers.
With the latest funds, the company will advance its GPR35 inhibitor program through critical investigational new drug (IND)-enabling studies. As they progress through preclinical development, their scientific approach underscores a commitment to tackling complex medical challenges in the GI space, building on their expertise and thought leadership in GPR35 biology.
Since its inception, ThirtyFiveBio has raised nearly $25M in financing, primarily driven by its innovative drug discovery platform created in partnership with Molecule to Medicine (MTM) and Canaan Partners. This financial backing not only fuels R&D efforts but also positions the company favorably in the eyes of potential investors looking for scalable solutions in the amazing realm of biomedicine. As they move forward, the industry will be eagerly watching how ThirtyFiveBio transforms its vision into a reality that could impact countless lives suffering from GI diseases.
Key Terms Explained
- Funding
- It refers to the act of providing financial resources, typically in the form of money, or other values such as time or effort, in order to finance a need, a program, or a project.
- G protein-coupled receptor 35 (GPR35)
- GPR35 is a protein-coding gene that is a subject of medical research and drug development due to its potential role in treating certain diseases. In this context, it's a molecular target for drugs being developed by the startup.
- Investigational new drug (IND)-enabling studies
- These are pre-clinical studies done with new drugs before they are approved for testing in humans. This is a necessary step before the drug can be trialed in clinical studies to determine its safety and efficacy.
Frequently Asked Questions
- What is ThirtyFiveBio's primary focus in the biotechnology industry?-ThirtyFiveBio's primary focus is the development of small molecule inhibitors targeting the G protein-coupled receptor 35 (GPR35), promising in the treatment of conditions like colitis and GI-related cancers.
- Which investors participated in the funding round of ThirtyFiveBio?+
- What is the significance of ThirtyFiveBio's recent funding?+
- How much has ThirtyFiveBio raised in financing since its inception?+
- What is the purpose of the funds raised by ThirtyFiveBio?+
They've invested in ThirtyFiveBio
Get to know these Biotech investors
Click here for a full list of 6,908+ startup investors in the UK